cruiser osr flydende bejdse
syngenta nordics a/s - fludioxonil, thiamethoxam, metalaxyl-m - flydende bejdse - 8 g/l fludioxonil ; 280 g/l thiamethoxam ; 33,3 g/l metalaxyl-m
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystisk fibrose - andet respirationssystem produkter - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukæmi, hårete celler - antineoplastiske midler - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
ontilyv
bial portela & companhia s.a. - opicapone - parkinsons sygdom - anti-parkinson-lægemidler - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
clopidogrel teva pharma b.v.
teva pharma b.v. - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiske midler - forebyggelse af atherothrombotic eventsclopidogrel er angivet i:voksne patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom;voksne patienter, der lider af akut koronar syndrom: non-st-segment elevation akut koronar syndrom (ustabil angina pectoris eller non-q-tak myokardieinfarkt), herunder patienter, der gennemgår en stent placering efter perkutan koronar intervention, i kombination med acetylsalicylsyre (asa);st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. forebyggelse af atherothrombotic og tromboemboliske hændelser i atrial fibrillationin voksne patienter med atrieflimren, der har mindst en risikofaktor for vaskulære hændelser, er ikke egnede til behandling med vitamin-k-antagonister (vka), og som har en lav risiko for blødning, clopidogrel er indiceret i kombination med asa til forebyggelse af atherothrombotic og tromboemboliske hændelser, herunder slagtilfælde.
gablofen 0,5 mg/ml injektions-/infusionsvæske, opløsning, fyldt injektionssprøjte
piramal critical care b.v. - baclofen - injektions-/infusionsvæske, opløsning, fyldt injektionssprøjte - 0,5 mg/ml
gablofen 2 mg/ml injektions-/infusionsvæske, opløsning, fyldt injektionssprøjte
piramal critical care b.v. - baclofen - injektions-/infusionsvæske, opløsning, fyldt injektionssprøjte - 2 mg/ml
sportak ew olie i vand emulsion
basf a/s - prochloraz - olie i vand emulsion - 450 g/l prochloraz
cedomon flydende middel
bioagri ab / lantmännen bioagri - pseudomonas - flydende middel - 10000000000 cfu/ml pseudomonas chlororaphis stamme ma342
sarclisa
sanofi winthrop industrie - isatuximab - multipelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.